MX2022010672A - Dpp3 para la guia, monitoreo y estratificacion terapeutica de anticuerpos nt-adm en pacientes con choque. - Google Patents

Dpp3 para la guia, monitoreo y estratificacion terapeutica de anticuerpos nt-adm en pacientes con choque.

Info

Publication number
MX2022010672A
MX2022010672A MX2022010672A MX2022010672A MX2022010672A MX 2022010672 A MX2022010672 A MX 2022010672A MX 2022010672 A MX2022010672 A MX 2022010672A MX 2022010672 A MX2022010672 A MX 2022010672A MX 2022010672 A MX2022010672 A MX 2022010672A
Authority
MX
Mexico
Prior art keywords
dpp3
shock
stratification
monitoring
adm
Prior art date
Application number
MX2022010672A
Other languages
English (en)
Spanish (es)
Inventor
Andreas Bergmann
Original Assignee
4TEEN4 Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4TEEN4 Pharmaceuticals GmbH filed Critical 4TEEN4 Pharmaceuticals GmbH
Publication of MX2022010672A publication Critical patent/MX2022010672A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/26Infectious diseases, e.g. generalised sepsis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2022010672A 2020-02-27 2021-02-26 Dpp3 para la guia, monitoreo y estratificacion terapeutica de anticuerpos nt-adm en pacientes con choque. MX2022010672A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20159848 2020-02-27
PCT/EP2021/054911 WO2021170838A1 (en) 2020-02-27 2021-02-26 Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock

Publications (1)

Publication Number Publication Date
MX2022010672A true MX2022010672A (es) 2022-09-23

Family

ID=69742802

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010672A MX2022010672A (es) 2020-02-27 2021-02-26 Dpp3 para la guia, monitoreo y estratificacion terapeutica de anticuerpos nt-adm en pacientes con choque.

Country Status (9)

Country Link
US (1) US20230193348A1 (https=)
EP (1) EP4111204A1 (https=)
JP (2) JP2023516615A (https=)
CN (1) CN115244401A (https=)
AU (1) AU2021228207A1 (https=)
BR (1) BR112022015215A2 (https=)
CA (1) CA3172349A1 (https=)
MX (1) MX2022010672A (https=)
WO (1) WO2021170838A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022010564A (es) * 2020-02-27 2022-11-30 Adrenomed Ag Aglutinante anti-adrenomedulina (adm) para usarse en terapia de pacientes en choque.
KR20250042158A (ko) 2022-07-29 2025-03-26 아드레노메드 아게 쇼크의 요법 또는 예방에 사용하기 위한 항-아드레노메둘린 (ADM) 항체 또는 항-ADM 항체 단편 또는 항-ADM 비-Ig 스캐폴드
CN119630969A (zh) 2022-07-29 2025-03-14 4Teen4制药有限公司 预测患有败血症性休克的患者中的dpp3增加
WO2025248139A1 (en) 2024-05-31 2025-12-04 4TEEN4 Pharmaceuticals GmbH Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
JP2774769B2 (ja) 1993-04-26 1998-07-09 賢治 寒川 アドレノメデュリン
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
RU2004109222A (ru) 2001-08-30 2005-10-20 Байорексис Фармасьютикал Корпорейшн (Us) Слитые белки модифицированного трансферрина
WO2003103475A2 (en) 2002-06-07 2003-12-18 Dyax Corp. Prevention and reduction of blood loss
EP1620734A1 (en) 2003-04-25 2006-02-01 Genova Ltd. Secreted polypeptide species reduced cardiovascular disorders
WO2005040229A2 (en) 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
US20070280886A1 (en) 2004-09-09 2007-12-06 Bayer Healthcare Ag Diagnostics and Therapeutics for Diseases Associated with Adrenomedullin Receptor (Amdr)
US8278262B2 (en) 2004-09-21 2012-10-02 Biontech Ag Use of microproteins as tryptase inhibitors
DK2231860T3 (da) 2007-12-19 2011-12-05 Affibody Ab Polypeptid afledt protein A og i stand til at binde PDGF
EP3785735A1 (en) 2008-11-03 2021-03-03 Molecular Partners AG Binding proteins inhibiting the vegf-a receptor interaction
MX2012002428A (es) 2009-08-27 2012-09-12 Covagen Ag Compuestos de union il-17 y usos medicos de los mismos.
AU2010332932B2 (en) 2009-12-14 2013-01-17 Navigo Proteins Gmbh Modified ubiquitin proteins having a specific binding activity for the extradomain B of fibronectin
RU2569745C2 (ru) 2010-06-08 2015-11-27 Пиерис АГ Мутеины липокалина слезы, связывающие альфа il-4 r
PL2594588T3 (pl) 2011-11-16 2014-11-28 Adrenomed Ag Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zastosowania w terapii
EP2780370B1 (en) 2011-11-16 2019-09-25 AdrenoMed AG Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
SG11201402362VA (en) 2011-11-16 2014-06-27 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
DK2780371T3 (en) 2011-11-16 2019-02-25 Adrenomed Ag ANTI-ADDRENOMEDULLIN (ADM) ANTIBODY OR ANTI-ADM ANTISTOFFRAGMENT OR ANTI-ADM NON-IG TEMPLATE FOR REGULATING LIQUID BALANCE OF A PATIENT WITH A CHRONIC OR ACUTE DISEASE
EP4086283A1 (en) 2011-11-16 2022-11-09 AdrenoMed AG Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
AU2017252212B2 (en) * 2016-04-21 2023-09-07 4TEEN4 Pharmaceuticals GmbH Methods for determining DPP3 and therapeutic methods
SG11202002268XA (en) * 2017-10-18 2020-04-29 Adrenomed Ag Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder
MY202502A (en) * 2017-10-25 2024-05-01 4TEEN4 Pharmaceuticals GmbH Dpp3 binder directed to and binding to specific dpp3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress

Also Published As

Publication number Publication date
US20230193348A1 (en) 2023-06-22
CN115244401A (zh) 2022-10-25
JP2026035582A (ja) 2026-03-04
AU2021228207A1 (en) 2022-10-20
WO2021170838A1 (en) 2021-09-02
BR112022015215A2 (pt) 2022-10-11
EP4111204A1 (en) 2023-01-04
JP2023516615A (ja) 2023-04-20
CA3172349A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
MX2022010672A (es) Dpp3 para la guia, monitoreo y estratificacion terapeutica de anticuerpos nt-adm en pacientes con choque.
MX2018003376A (es) Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23.
MX2022006075A (es) Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer.
EA202091810A1 (ru) Антитела к b7-h4 и способы их применения
MX2022000128A (es) Desarrollo de clasificadores para estratificar pacientes.
EA201391587A1 (ru) Комбинированная терапия на основе hsp90
MX374652B (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco.
EP4417218A3 (en) Methods for determining dpp3 and therapeutic methods
RU2013104301A (ru) Способ идентификации пациента с повышенной вероятностью ответа на противораковую терапию
NZ601111A (en) Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies
EP4552649A3 (en) Therapy guidance and/or therapy monitoring for treatment of shock
EA201890106A1 (ru) Способы лечения аутоиммунных и аллоиммунных расстройств
MX2022001087A (es) Ergotioneina, s-metil-ergotioneina, y usos de las mismas.
EA201892542A1 (ru) Способы прогнозирования у пациентов терапевтического эффекта терапии с использованием антител к cd19
NZ766385A (en) Biomarkers of methotrexate-induced immune tolerance
EP4502182A3 (en) Diagnostic and therapeutic methods for the treatment of rheumatoid arthritis (ra)
MX2018007589A (es) Ccl20 como indicador de respuesta clinica a antagonistas de il23.
WO2018064013A8 (en) METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR
EA201490576A1 (ru) Молекулярный маркер для ранней диагностики мезотелиомы плевры у пациентов и способы для анализа его экспрессии
NZ796051A (en) S100 proteins as novel therapeutic targets in myeloproliferative neoplasms
IL308510A (en) Method, device and program for searching for a new diagnostic biomarker and/or therapeutic target
EA201891693A1 (ru) Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака, посредством измерения уровня биомаркера в плазме крови
MX2025002786A (es) Anticuerpos contra el fentanilo y analogos y metodos de uso de estos
WO2019053117A8 (en) Pct and pro-adm as markers for monitoring antibiotic treatment
WO2019053116A8 (en) Method for guidance of fluid therapy based on proadrenomedullin